

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

BACKGROUND

Reference is made to the announcement of the Company dated July 4, 2025 in relation to the fact that the Company has entered into the subscription agreements with PDB to subscribe for certain wealth management products offered by PDB. As of the date of this announcement, all the wealth management products subscribed by the Company from PDB have been redeemed.

SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT

The Board announces that on March 23, 2026, in order to effectively utilize its idle funds, the Company entered into a subscription agreement with PDB to subscribe for wealth management product offered by PDB, the principal terms of which are set out below.

The Company agreed to subscribe for wealth management product offered by PDB with a principal amount of RMB100 million and a maturity date of September 23, 2026 (the “**PDB Subscription**”), details of which are set out below:

Product name	Confirmation date of subscription	Maturity date	Principal amount of subscription	Expected yield of the product (per annum)	Product type	Risk level of the product
Liduoduo Corporate Stable Profit 26JG6372 (Three Level Bullish) RMB Public Structured Deposit (利多多公司穩利26JG6372期(三層看漲)人民幣對公結構性存款)	March 23, 2026	September 23, 2026	RMB100 million	The product has a guaranteed yield of 0.95% and a floating yield of 0% or 1.05% (mid-range floating yield) or 1.25% (high-range floating yield)	Principal-guaranteed floating-yield type	Low risk (internal risk assessment results of PDB, for reference only)

BASIS OF CONSIDERATION

The Board confirms that the consideration for the PDB Subscription was determined in accordance with commercial terms negotiated at arm's length between the Company and PDB, taking into account (i) the then surplus cash available to the Company for capital management; (ii) the expected investment return and terms of the subscription; and (iii) prevailing market interest rates and practices. The subscription was financed by the Company's own funds (other than the proceeds from the initial public offering).

INFORMATION OF THE PARTIES

Qyuns

The Company was incorporated in the PRC in 2015 and its shares are listed on the Main Board of the Stock Exchange (stock code: 2509). The Company is a biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline and mature commercial-scale in-house manufacturing capacity. The Company's product pipeline covers four major areas in the autoimmune and allergic disease field, namely, skin, rheumatic, respiratory and digestive diseases.

PDB

To the best knowledge of the Directors, PDB is a commercial bank principally engaged in banking services and its shares are listed on the Shanghai Stock Exchange (stock code: 600000).

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, based on the public information available to the Company, PDB and its ultimate beneficial owners are third parties independent of the Company and its connected persons.

REASONS FOR AND BENEFITS OF THE SUBSCRIPTION

The Company made the subscription for the purpose of capital management to maximize the use of its idle funds in order to achieve a balanced return while maintaining a high level of liquidity and a low level of risk. Taking into account, among other things, the low level of risk and the expected yield of the wealth management product, the Company is of the view that the subscription will provide the Group with a better yield than those of the deposits generally offered by commercial banks and will enhance the overall profitability of the Company. The Company has monitored and managed the subscription closely and effectively and will continue to monitor and manage the subscription closely and effectively.

Having considered that the subscription is a principal-guaranteed floating-yield bank structured deposit which has been carefully assessed and categorized as of relatively low risk and with reference to similar products in the market and their general yields, the Board is of the view that the terms of the subscription are fair and reasonable and in the best interests of the Company and its Shareholders as a whole. The Group has implemented adequate and appropriate internal control procedures to ensure that the subscription will not affect the working capital or operations of the Group and that such investments will be made under the principle of safeguarding the interests of the Company and its Shareholders as a whole.

LISTING RULES IMPLICATIONS

As the highest applicable percentage ratio in respect of the PDB Subscription exceeds 5% but is less than 25%, the PDB Subscription constitutes a discloseable transaction of the Company under the Listing Rules, and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings.

“Board”	the board of Directors of the Company
“Company”	Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司), a limited liability company incorporated in the PRC in 2015, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2509)
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PDB”	Shanghai Pudong Development Bank Co., Ltd. (上海浦東發展銀行股份有限公司)
“PDB Subscription”	subscription by the Company for wealth management product (26JG6372) offered by PDB with a principal amount of RMB100 million and a maturity date of September 23, 2026
“PRC”	the People’s Republic of China, and for the purpose of this announcement only, excludes the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the PRC and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	shareholders of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, March 23, 2026

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive directors.